<DOC>
	<DOCNO>NCT02494583</DOCNO>
	<brief_summary>This study pembrolizumab ( MK-3475 ) first-line treatment participant advance gastric gastroesophageal junction ( GEJ ) adenocarcinoma . Participants randomly assign one 3 treatment arm study : pembrolizumab monotherapy , pembrolizumab + cisplatin + 5-fluorouracil ( 5-FU ) capecitabine , placebo + cisplatin + 5-FU capecitabine . The primary hypothesis pembrolizumab provide clinically meaningful progression free and/or overall survival .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) First-Line Monotherapy Combination Therapy Treatment Advanced Gastric Gastroesophageal Junction Adenocarcinoma ( MK-3475-062/KEYNOTE-062 )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale within 3 day prior first dose study medication Have histologically cytologicallyconfirmed diagnosis locally advance unresectable metastatic gastric GEJ adenocarcinoma HER2/neu protein negative program cell death ligand 1 ( PDL1 ) positive Have measurable disease Female participant childbearing potential must willing use adequate contraception surgically sterile , abstain heterosexual activity course study 120 day last dose study medication Male participant childbearing potential agree use adequate method contraception start first dose study medication 120 day last dose study medication Adequate organ function Squamous cell undifferentiated gastric cancer Previous therapy locally advance , unresectable metastatic gastric/GEJ cancer . Participant may receive prior neoadjuvant adjuvant therapy long complete least 6 month prior randomization Major surgery , open biopsy significant traumatic injury within 28 day prior randomization , anticipation need major surgery course study treatment . Radiotherapy within 14 day randomization Known additional malignancy progress require active treatment exception basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Active autoimmune disease require systemic treatment past 2 year Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication History noninfectious pneumonitis require steroid current pneumonitis Active infection require systemic therapy Pregnant , breastfeeding , expect conceive father child within project duration trial , start screen visit 180 day last dose study medication Prior therapy antiprogrammed cell death ( PD ) 1 , antiPDL1 , antiPDL2 agent Known history human immunodeficiency virus ( HIV ) Known active Hepatitis B C Currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week prior first dose study medication Received live vaccine within 30 day plan start study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gastric carcinoma</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Gastroesophageal junction cancer</keyword>
	<keyword>Gastroesophageal junction carcinoma</keyword>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>